共 50 条
- [35] Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review [J]. FRONTIERS IN ONCOLOGY, 2022, 12
- [36] PePS2: Pembrolizumab in Performance Status 2 non-small-cell lung cancer [J]. LUNG CANCER, 2017, 103 : S76 - S76
- [38] Acute development of fatal myocarditis after pembrolizumab in non-small-cell lung cancer with thymoma [J]. CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2021, 4
- [40] Second-line erlotinib for non-small-cell lung cancer Reply [J]. LANCET ONCOLOGY, 2012, 13 (04) : E142 - E142